BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dal Bo M, De Mattia E, Baboci L, Mezzalira S, Cecchin E, Assaraf YG, Toffoli G. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 2020;51:100702. [DOI: 10.1016/j.drup.2020.100702] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Su Z, Dong S, Zhao SC, Liu K, Tan Y, Jiang X, Assaraf YG, Qin B, Chen ZS, Zou C. Novel nanomedicines to overcome cancer multidrug resistance. Drug Resist Updat 2021;58:100777. [PMID: 34481195 DOI: 10.1016/j.drup.2021.100777] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 2021;11:3489-501. [PMID: 33537099 DOI: 10.7150/thno.54648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
3 Boettcher M, Joechner A, Li Z, Yang SF, Schlegel P. Development of CAR T Cell Therapy in Children-A Comprehensive Overview. J Clin Med 2022;11:2158. [PMID: 35456250 DOI: 10.3390/jcm11082158] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Shrestha R, Bridle KR, Crawford DHG, Jayachandran A. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. Int J Med Sci 2021;18:2466-79. [PMID: 34104078 DOI: 10.7150/ijms.54239] [Reference Citation Analysis]
5 Song HY, Xia JS, Chen YG, Chen L. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro. Hum Exp Toxicol 2021;40:S646-53. [PMID: 34784831 DOI: 10.1177/09603271211052989] [Reference Citation Analysis]
6 Song HY, Xia JS, Chen YG, Chen L. Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells in vitro. Hum Exp Toxicol 2022;41:9603271221080236. [PMID: 35099304 DOI: 10.1177/09603271221080236] [Reference Citation Analysis]
7 Song G, Zhu X, Xuan Z, Zhao L, Dong H, Chen J, Li Z, Song W, Jin C, Zhou M, Xie H, Zheng S, Song P. Hypermethylation of GNA14 and its tumor-suppressive role in hepatitis B virus-related hepatocellular carcinoma. Theranostics 2021;11:2318-33. [PMID: 33500727 DOI: 10.7150/thno.48739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
8 Xue C, Gu X, Li L. Immune classifier-based signatures provide good prognostic stratification and predict the clinical benefits of immune-based therapies for hepatocellular carcinoma. Cancer Cell Int 2021;21:471. [PMID: 34488768 DOI: 10.1186/s12935-021-02183-5] [Reference Citation Analysis]
9 Zheng Q, Yang Q, Zhou J, Gu X, Zhou H, Dong X, Zhu H, Chen Z. Immune signature-based hepatocellular carcinoma subtypes may provide novel insights into therapy and prognosis predictions. Cancer Cell Int 2021;21:330. [PMID: 34193146 DOI: 10.1186/s12935-021-02033-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Icard P, Simula L, Wu Z, Berzan D, Sogni P, Dohan A, Dautry R, Coquerel A, Lincet H, Loi M, Fuks D. Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma? Drug Resist Updat 2021;:100790. [PMID: 34924279 DOI: 10.1016/j.drup.2021.100790] [Reference Citation Analysis]
11 Hofmann J, Hackl V, Esser H, Meszaros AT, Fodor M, Öfner D, Troppmair J, Schneeberger S, Hautz T. Cell-Based Regeneration and Treatment of Liver Diseases. Int J Mol Sci 2021;22:10276. [PMID: 34638617 DOI: 10.3390/ijms221910276] [Reference Citation Analysis]
12 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
13 Atwa SM, Odenthal M, M El Tayebi H. Genetic Heterogeneity, Therapeutic Hurdle Confronting Sorafenib and Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4343. [PMID: 34503153 DOI: 10.3390/cancers13174343] [Reference Citation Analysis]
14 Pérez-Ruiz E, Melero I, Kopecka J, Sarmento-Ribeiro AB, García-Aranda M, De Las Rivas J. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies. Drug Resist Updat 2020;53:100718. [PMID: 32736034 DOI: 10.1016/j.drup.2020.100718] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 11.0] [Reference Citation Analysis]
15 Damiris K, Abbad H, Pyrsopoulos N. Cellular based treatment modalities for unresectable hepatocellular carcinoma. World J Clin Oncol 2021; 12(5): 290-308 [PMID: 34131562 DOI: 10.5306/wjco.v12.i5.290] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kopecka J, Salaroglio IC, Perez-Ruiz E, Sarmento-Ribeiro AB, Saponara S, De Las Rivas J, Riganti C. Hypoxia as a driver of resistance to immunotherapy. Drug Resist Updat 2021;:100787. [PMID: 34840068 DOI: 10.1016/j.drup.2021.100787] [Reference Citation Analysis]
17 Yao F, Zhan Y, Li C, Lu Y, Chen J, Deng J, Wu Z, Li Q, Song Y, Chen B, Chen J, Tian K, Pu Z, Ni Y, Mou L. Single-Cell RNA Sequencing Reveals the Role of Phosphorylation-Related Genes in Hepatocellular Carcinoma Stem Cells. Front Cell Dev Biol 2021;9:734287. [PMID: 35059393 DOI: 10.3389/fcell.2021.734287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Yu Y, Su X, Qin Q, Hou Y, Zhang X, Zhang H, Jia M, Chen Y. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases. Pharmacological Research 2020;159:105009. [DOI: 10.1016/j.phrs.2020.105009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
19 Gonçalves AC, Richiardone E, Jorge J, Polónia B, Xavier CPR, Salaroglio IC, Riganti C, Vasconcelos MH, Corbet C, Sarmento-Ribeiro AB. Impact of cancer metabolism on therapy resistance - Clinical implications. Drug Resist Updat 2021;:100797. [PMID: 34955385 DOI: 10.1016/j.drup.2021.100797] [Reference Citation Analysis]
20 Icard P, Simula L, Fournel L, Leroy K, Lupo A, Damotte D, Charpentier MC, Durdux C, Loi M, Schussler O, Chassagnon G, Coquerel A, Lincet H, De Pauw V, Alifano M. The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications. Drug Resist Updat 2022;63:100852. [PMID: 35849943 DOI: 10.1016/j.drup.2022.100852] [Reference Citation Analysis]
21 Yang S, Cheng Y, Wang X, Wei P, Wang H, Tan S. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy. Front Genet 2021;12:777931. [PMID: 34899862 DOI: 10.3389/fgene.2021.777931] [Reference Citation Analysis]
22 Leone V, Ali A, Weber A, Tschaharganeh DF, Heikenwalder M. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [PMID: 33674229 DOI: 10.1016/j.trecan.2021.01.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Meng X, Dong S, Yangyang L, Wang S, Xu X, Liu T, Zhuang X. Adenosine triphosphate-binding cassette subfamily C members in liver hepatocellular carcinoma: Bioinformatics-driven prognostic value. Medicine (Baltimore) 2022;101:e28869. [PMID: 35363194 DOI: 10.1097/MD.0000000000028869] [Reference Citation Analysis]
24 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
25 Guan MC, Wang MD, Liu SY, Ouyang W, Liang L, Pawlik TM, Xu QR, Huang DS, Shen F, Zhu H, Yang T. Early diagnosis and therapeutic strategies for hepatocellular carcinoma: From bench to bedside. World J Gastrointest Oncol 2021; 13(4): 197-215 [PMID: 33889272 DOI: 10.4251/wjgo.v13.i4.197] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Jiang T, Chen X, Ren X, Yang JM, Cheng Y. Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance. Drug Resist Updat 2021;56:100752. [PMID: 33765484 DOI: 10.1016/j.drup.2021.100752] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Dinić J, Efferth T, García-Sosa AT, Grahovac J, Padrón JM, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I. Repurposing old drugs to fight multidrug resistant cancers. Drug Resist Updat 2020;52:100713. [PMID: 32615525 DOI: 10.1016/j.drup.2020.100713] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
28 Chiappa M, Guffanti F, Bertoni F, Colombo I, Damia G. Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer. Drug Resist Updat 2021;55:100744. [PMID: 33551306 DOI: 10.1016/j.drup.2021.100744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
29 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]